Issues
-
Cover Image
Cover Image
Microsatellite-stable colorectal cancer (MSS CRC) is often resistant to immune checkpoint inhibitor treatment due to an immune-excluding and -suppressive microenvironment. Wu et al. identified stromal chondroitin sulfate metabolism, specifically metabolism of the C-6-S subtype, as a driver of establishing an immune-exclusion barrier and polarizing suppressive macrophages via JAK/STAT and Hedgehog signaling in MSS CRC. Treating tumor-bearing mice with C-6-S antagonists reversed the immune-exclusive and -suppressive microenvironment, reduced tumor growth, and increased the efficacy of anti–PD-1 therapy. This work highlights the role of stroma-derived factors in tumor immune evasion and demonstrates a potential therapeutic strategy for targeting immunotherapy-resistant tumors. Read more in this issue on page 182. Original image from Fig. 3G. Artwork by Lewis Long. - PDF Icon PDF LinkTable of Contents
- PDF Icon PDF LinkEditorial Board
Cancer Immunology Research
Cancer Immunology Research, launched in 2013 with Glenn Dranoff as founding Editor-in-Chief, is published by the AACR. The Journal illuminates the interplay between tumors and the immune system, with Robert D. Schreiber and Philip D. Greenberg serving as the Editors-in-Chief.
Table of Contents
What We’re Reading
Review
Priority Brief
NKG7 Is Required for Optimal Antitumor T-cell Immunity
NKG7 is a cytotoxic lymphocyte granule protein. In this study, NKG7 is shown to be critical for the natural antitumor immunity of CD8+ T cells and for optimal immune-checkpoint blockade therapy.
Research Articles
NKG7 Is a T-cell–Intrinsic Therapeutic Target for Improving Antitumor Cytotoxicity and Cancer Immunotherapy
NKG7 is a cytolytic granule-associated protein. The authors show that NKG7 is critical for cytotoxic CD8+ T-cell antitumor activity and that NKG7 mRNA transfection improves tumor-cell killing by CD8+ T cells, identifying NKG7 as a potential therapeutic target.
Remodeling Chondroitin-6-Sulfate–Mediated Immune Exclusion Enhances Anti–PD-1 Response in Colorectal Cancer with Microsatellite Stability
Immunomodulation of T- and NK-cell Responses by a Bispecific Antibody Targeting CD28 Homolog and PD-L1
Spatial Organization and Prognostic Significance of NK and NKT-like Cells via Multimarker Analysis of the Colorectal Cancer Microenvironment
PRDX-1 Supports the Survival and Antitumor Activity of Primary and CAR-Modified NK Cells under Oxidative Stress
Expansion of Candidate HPV-Specific T Cells in the Tumor Microenvironment during Chemoradiotherapy Is Prognostic in HPV16+ Cancers
Journal Archive
Cancer Immunology Research
(2013-Present)Published monthly since 2013.
(ISSN 2326-6066)
Cancer Immunity
(2001-2013; volumes 1-13)Published periodically from 2001-2013.
(EISSN 1424-9634)
Advertisement
Email alerts
NOTICE: This notice serves to inform the reader that, in 2023, AACR received a donation by Pfizer of the rights to royalties from the sale—within the United States—of Bavencio® (avelumab), a pharmaceutical owned by Merck. None of these funds are being, or will be, used to directly support any specific publication or author. If an individual article is published that deals with this particular drug, such article will include standard financial disclosures per AACR journal policy. For more detail regarding AACR’s established policies for authors, please go to https://aacrjournals.org/pages/editorial-policies#coi.
RSS Feeds